Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines

Current Medicinal Chemistry

Volumn 5, Issue 1, 1998, Pages 1-28

  Hasinoff, B B ^a   Hellmann, K ^b   Herman, E H ^c   Ferrans, V J ^d  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Windleshaw House   (United Kingdom)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 PROPANEDIAMINE N,N' DIACETAMIDE N,N' DIACETIC ACID; ALLOXAN; ANTHRACYCLINE DERIVATIVE; BLEOMYCIN; DAUNORUBICIN; DOXORUBICIN; EDETIC ACID; IRON COMPLEX; PIPERAZINE DERIVATIVE; RAZOXANE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; CARDIOTOXICITY; CELL CULTURE; DRUG HYDROLYSIS; DRUG STRUCTURE; HAMSTER; HEART PROTECTION; HUMAN; MOUSE; NONHUMAN; RADIOSENSITIZATION; REVIEW;

ANIMALS; ANTHRACYCLINES; DOXORUBICIN; HEART; IRON CHELATING AGENTS; MOLECULAR STRUCTURE; OXIDATIVE STRESS; PIPERAZINES; RAZOXANE;

EID: 0031906718     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (223)

1. Swain, S. M.; Whaley, F. S.; Gerber, M. C.; Weisberg, S.; York, M.; Spicer, D.; Jones, S. E., Wadler, S.; Desai, A.; Vogel, C.; Speyer, J.; Mittelman, A.; Reddy, S.; Pendergrass, K.; Velez-Garcia, E.; Ewer, M. S.; Bianchine, J. R.; Gams, R. A. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J. Clin. Oncol. 1997, 15, 1318-1332.
2. Swain, S. M.; Whaley, F.; Gerber, M. C.; Ewer, M. S.; Bianchine, J. R.; Gams, R. A. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J. Clin. Oncol. 1997, 15, 1333-1340.
3. Wexler, L. H.; Andrich, M. P.; Venzon, D.; Berg, S. L.; Weaver-McClure, L.; Chen, C. C.; Dilsizian, V.; Avila, N.; Jarosinski, P.; Balis, F. M.; Poplack, D. G.; Horowitz, M. E. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J. Clin. Oncol. 1996, 14, 362-372.
4. Gianni, L.; Corden, B. J.; Myers, C. E. The biochemical basis of anthracycline toxicity and anti-tumor activity. Rev. Biochem. Toxicol. 1983, 5, 1-82.
5. Weiss, R. B. The anthracyclines: will we ever find a better doxorubicin? Semin. Oncol. 1992, 19, 670-686.
6. Gutteridge, J. M. C. Lipid peroxidation and possible hydroxyl radical formation stimulated by the self-reduction of a doxorubicin-iron(III) complex. Biochem. Pharmacol. 1984, 33, 1725-1728.
7. Myers, C. E.; Gianni, L.; Simone, C. B.; Klecker, R.; Greene, R. Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex. Biochemistry 1982, 21, 1707-1713.
8. Gianni, L.; Zweier, J. L.; Levy, A.; Myers, C. E. Characterization of the cycle of iron-mediated electron transfer from adriamycin to molecular oxygen. J. Biol. Chem. 1985, 260, 6820-6826.
9. Demant, E. J. F.; Jensen, P. K. Destruction of phospholipids and respiratory-chain activity in pig-heart submitochondrial particles induced by an adriamycin-iron complex. Eur. J. Biochem. 1983, 132, 551-556.
10. Malisza, K. L.; Hasinoff, B. B. Production of hydroxyl radical by iron(III)-anthraquinone complexes through self-reduction and through reductive activation by the xanthine oxidase/hypoxanthine system. Arch. Biochem. Biophys. 1995, 321, 51-60.
11. Halliwell, B.; Gutteridge, J. M. C. Free Radicals in Biology and Medicine, 2nd ed.; Clarendon: Oxford, 1989.
12. Kiraly, R.; Martin, R. B. Metal ion binding to daunomycin and quinizann Inorg. Chim. Acta 1982, 67, 13-18.
13. Gelvan, D.; Samuni, A. Reappraisal of the association between adriamycin and iron. Cancer Res. 1988, 48, 5645-5649.
14. May, P. M.; Williams, G. K.; Williams, D. R. Speciation studies of adriamycin, quelamycin, and their metal ion complexes. Inorg. Chim. Acta 1980, 46, 221-228.
15. 2 by iron-adriamycin. J. Biol. Chem. 1984, 253, 6056-6058.
16. 2 reduction by the iron complexes of adriamycin and daunomycin: the importance of the sidechain hydroxyl group. Biochim. Biophys. Acta 1986, 884, 326-336.
17. Gianni, L.; Vigano, L.; Lanzi, C.; Niggeler, M.; Malatesta, V. Role of daunosamine and hydroxyacetyl side chain in reaction with iron and lipid peroxidation by anthracyclines. J. Natl. Cancer Inst. 1988, 80, 1104-1111.
18. Gelvan, D.; Berg, E.; Saltman, P.; Samuni, A. Time-dependent modifications of fernc-adriamycin. Biochem. Pharmacol. 1990, 39, 1289-1295.
19. Fiallo, M.; Laigle, A.; Garnier-Suillerot, A.; Amirand, C.; Ballini, J.-P.; Chinsky, L.; Duquesne, M.; Jolies, B.; Sureau, F.; Turpin, P.-Y.; Vigny, P. Interactions of iron-anthracycline complexes with living cells: a microspectrofluorometric study. Biochim. Biophys. Acta. 1993, 1177, 236-244.
20. Malatesta, V. In Free Radicals in Synthesis and Biology, Minisci. F., Ed.; Kluwer Academic Publishers: Dordrecht. 1989; pp. 437-460.
21. Hasinoff, B. B. Self-reduction of the iron(III)-doxorubicin complex. Free Rad. Biol. Med. 1989, 7, 583-593.
22. 3+-doxorubicin complex undergoing self-reduction by its α-ketol group. Biochem. Cell. Biol. 1990, 68, 1331-1336.
23. Von Hoff, D. D.; Lazard, M. W.; Basa, P.; Davis, H. L.; Von Hoff, A. L.; Rozencweig, M.; Muggia, F. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 1979, 91, 710-717.
24. Von Hoff, D. D.; Rozencweig, M.; Layard, M.; Slavik, M.; Muggia, F. M. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am. J. Med. 1977, 62, 200-210.
25. Hasinoff, B. B. Inhibition and inactivation of NADH-cytochrome c reductase activity of bovine heart submitochondrial particles by the iron(III)-adriamycin. Biochem. J. 1990, 265, 865-870.
26. Hasinoff, B. B.; Davey, J. P. Adriamycin and its iron(III) and copper(II) complexes; glutathione-induced dissociation; cytochrome c oxidase inactivation and protection; binding to cardiolipin. Biochem. Pharmacol. 1988, 37, 3663-3669.
27. Bachur, N. R.; Gordon, S. L.; Gee, M. V.; Kon, H. NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. Proc. Natl. Acad. Sci. USA 1979, 76, 954-557.
28. Huang, Z.-X.; May, P. M.; Quinlan, K. M.; Williams, D. R.; Creighton, A. M. Metal binding by pharmaceuticals Part 2. Interactions of Ca(II), Cu(II), Fe(II), Mg(II), Mn(II) and Zn(II) with the intracellular hydrolysis products of the antitumor agent ICRF-159 and its inactive homologue ICRF-192. Agents Actions 1982, 72, 536-542.
29. Hershko, C.; Link, G.; Tzahor, M.; Pinson, A. The role of iron and iron chelators in anthracycline cardiotoxicity. Leuk. Lymphoma 1933, 11, 207-214.
30. Green, M. D.; Alderton, P.; Sobol, M. M.; Gross, J ; Muggia, F. M.; Speyer, J. L. In New Drugs, Concepts and Results in Cancer Chemotherapy, Muggia, F. M., Ed.; Kluwer Academic Publishers: Dordrecht, 1992; pp. 101-117.
31. Witiak, D T.; Wei, Y. In Progress in Drug Research; Jucker, E., Ed., Birkhauser Verlag: Basel, 1991; Vol. 35, pp 249-363.
32. Herman, E. H.; Witiak, D. T.; Hellmann, K.; Waravdekar, V. S. Biological properties of ICRF-159 and related bis(dioxopiperazine) compounds. Adv. Pharmacol. Chemother. 1982, 19, 249-290.
33. Nair, R. V.; Witiak, D T. The evolution of a cardioprotective antimetastatic and antitumor drug: An international adventure. J. Chem. Edu 1988, 65, 534-538.
34. Seifert, C. F.; Nesser, M. E., Thompson, D. F. Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. Ann. Pharmacother. 1994, 28, 1063-1072.
35. Witiak, D. T.; Herman, E. H. In Anthracycline Antiobiotics, New Analogues, Methods of Delivery, and Mechanisms of Action; Priebe, W., Ed.; American Chemical Society: Washington, 1995; pp. 268-299.
36. Blum, R. H ; Walsh, C.; Green, M. D.; Speyer, J. L. Modulation of the effect of anthracycline efficacy and toxicity by ICRF-187. Cancer Invest. 1990, 8, 267-268.
37. Hellmann, K. ICRF-187. J. Chemother. 1989, 1, 355-358.
38. Koning, J.; Palmer, P.; Franks, C. R.; Mulder, D. E.; Speyer, J. L.; Green, M. D.; Hellmann, K. Cardioxane-ICRF-187, towards anticancer drug specificity through selective toxicity reduction. Cancer Treat Rev. 1991, 18, 1-19.
39. Eastland, G. ICRF-187. Drugs Future 1987, 12, 1017-1020.
40. Bakowski, M. T. ICRF-159, (±) 1,2-di(3,5-dioxopiperazin-1-yl)propane NSC-129,943; Razoxane. Cancer Treat. Rev. 1976, 3, 95-107.
41. Bellet, R. E.; Rozencweig, M.; Von Hoff, D. D.; Penta, J. S.; Wasserman, T. H ; Muggia, F. M. ICRF-159: Current status and clinical prospects. Eur. J. Cancer 1977, 13, 1293-1298.
42. Repta, A. J.; Baltezor, M. J.; Bansal, P. C. Utilization of an enantiomer as a solution to a pharmaceutical problem: application to solubilization of 1,2-di(4-piperazine-2,6-dione)propane. J. Pharm. Sci. 1976, 65, 238-242.
43. Creighton, A. M. U. K. Patent 1,234,935, 1971.
44. Creighton, A M. U. K. Patent 1,374,979, 1974.
45. Creighton, A. M. U. S. Patent 3,941,790, 1976.
46. Geigy, J. R. U. K. Patent 961,065, 1964.
47. Snapka, R. M.; Woo, S. H.; Blokhin, A. V.; Witiak, D. T. Inhibition of topoisomerase Ii by ICRF-193, the meso isomer of 2,3-bis(2,6-dioxopiperazin-4-yl)butane. Critical dependence on 2,3-butanediyl linker absolute configuration. Biochem. Pharmacol. 1996, 52, 543-549.
48. Witiak, D. T.; Wei, Y. Synthesis and 1H NMR conformational analysis of Diastereomeric 4,4′-(4,5-dihydroxy-1,2-cyclohexanediyl)bis(2,6-piperazinedione)s and a synthetically related tricyclic octahydro-2,2-dimehtyl-6-oxo-1,3-dioxolo[4,5-g]quinoline-5,8-diacetic acid ester. J. Org. Chem. 1991, 56, 5408-5417.
49. Witiak, D. T.; Nair, R. V.; Schmid, F. A. Synthesis and antimetastatic properties of stereoisomeric tricyclic bis(dioxopiperazines) in the lewis lung carcinoma model. J. Med. Chem. 1985, 28, 1228-1234.
50. Witiak, D. T.; Trivedi, B. K.; Campolito, L. B ; Zwilling, B. S.; Reiches, N. A. Synthesis and antimetastatic properties of stereoisomeric tricyclic bis(dioxopiperazine) analogues in a B16 melanoma model. J. Med. Chem. 1981, 24, 1329-1332.
51. Witiak, D. T.; Lee, H. J.; Goldman, H. D.; Zwilling, B. S. Stereoselective effects of cis- and trans-cyclopropylbis(dioxopiperazines) related to ICRF-159 on metastases of a hamster lung adenocarcinoma. J. Med. Chem. 1978, 27, 1194-1197.
52. Witiak, D. T.; Lee, H. J ; Hart, R. W.; Gibson, R. E. Study of trans-cyclopropylbis(diketopiperazine) and chelating agents related to ICRF 159. Cytotoxtcity, mutagenicity, and effects on scheduled and unscheduled DNA synthesis. J. Med. Chem. 1977, 20, 630-635.
53. Jeffery, W. A. Ph.D. Dissertation, Council for National Academic Awards, London, 1987.
54. Tanabe, K.; Ikegami, Y.; Ishida, R.; Andoh, T. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res. 1991, 51, 4903-4908.
55. Ishida, R.; Miki, T.; Narita, T.; Yul, R.; Sato, M.; Utsumi, K. R.; Tanabe, K.; Andoh, T. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res. 1991, 51, 4909-4916.
56. Insaf, S. S.; Danks, M. K.; Witiak, D. T. A structure-function analysis of DNA topoisomerase II inhibitors. Curr Med. Chem. 1996, 3, 437-466.
57. Hempel, A.; Camerman, N.; Camerman, A. Stereochemistry of the antitumor agent 4,4′-(1,2-propanediyl)bis(4-piperazine-2,6-dione): Crystal and molecular structures of the racemate (ICRF-159) and a soluble enantiomer (ICRF-187). J. Am. Chem. Soc. 1982, 105, 3453-3456.
58. Hempel, A.; Camerman, N.; Camerman, A. Stereochemistry of the conformationally restricted analogues of the antitumor agent ICRF-159. 2. Structures of the antimetastatically active and inactive isomers of a tricyclic analogue. J. Am. Chem. Soc. 1983, 105, 2350-2354.
59. Camerman, N.; Hempel, A.; Camerman, A. Bimolane: Structure determination indicates anticancer activity is attributable to ICRF-154. Science 1984, 225, 1165-1166.
60. Prout, C. K., Sanderson, D. S.; Couldwell, M. C. N,N′-methylethylenebis(N-methylcarbamylglycinato)copper(II) dihydrate and N,N′-ethylethylenebis(N-methylcarbamylglycinato)copper(II) dihydrate. Cryst. Struct. Comm. 1979, 8, 181-188.
61. Hasinoff, B. B.; Kuschak, T. I.; Yalowich, J. C.; Creighton, A. M. A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane). Biochem. Pharmacol. 1995, 50, 953-958.
62. Creighton, A. M.; Jeffery, W. A ; Long, J. In Medicinal Chemistry I. Proceedings of the 6th international symposium on medicinal chemistry, Simkins, M. A., Ed.; Research Studies Press: Forest Grove, Oregon, 1979; pp. 281-288.
63. Hasinoff, B. B. The hydrolysis-activation of the doxorubicin cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane). Drug Matab. Dispos. 1990, 18, 344-349.
64. Rosing, H.; Vangijn, R.; Huinink, W. W T ; Beijenen, J. H. High performance liquid chromatographic analysis of the cardioprotective agent dexrazoxane in human plasma and urine. J. Liq. Chrom. Ret. Technol. 1997, 20, 583-601.
65. Jakobsen, P.; Sorensen, B.; Bastholt, L ; Mirza, M. R.; Gjedde, S. B.; Moundsen, H. T.; Rose, C. The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR 529 given together with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast-cancer patients. Cancer Chemother. Pharmacol. 1994, 35, 45-52.
66. Basser, R. L.; Sobol, M. M., Duggan, G.; Cebon, J.; Rosenthal, M. A.; Mihaly, G.; Green, M. D. Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy. J. Clin. Oncol. 1994, 12, 1659-1666.
67. Hochster, H.; Liebes, L.; Wadler, S.; Oratz, R.; Wernz, J. C.; Meyers, M.; Green, M.; Slum, R. H.; Speyer, J. L. Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J. Natl. Cancer Inst 1992, 84, 1725-1730.
68. Vogel, C. L.; Gorowski, E.; Davila, E.; Eisenberger, M.; Kosinski, J.; Agarwal, R. P., Savaraj, N. Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors. Invest. New Drugs 1987, 5, 187-198.
69. Earhart, R. H.; Tutsch, K. D.; Koeller, J. M.; Rodriguez, R ; Robins, H. I.; Vogel, C. L.; Davis, H. L.; Tormey, D. C. Pharmacokinetics of (+)-1,2-di(3,5-dioxopiperazin-1-yl)propane intravenous infusions in adult cancer patients. Cancer Res. 1982, 42, 5255-5261.
70. Collins, M.; Fu, X.-C.; Greig, N.; Hellmann, K. Determination of razoxane by high-pressure liquid chromatography. J. Chromatogr. 1983, 274, 434-440.
71. Lewis, R. C.; Phillips, B. A.; Baldwin, J. R.; Rossi, D. T.; Narang, P. K. A sensitive and specific procedure for quantitation of ADR-529 in biological fluids by high-performance liquid chromatography (HPLC) with column switching and amperometric detection. Pharm. Res. 1992, 9, 101-108.
72. Burke, T. G.; Lee, T. D.; van-Balgooy, J.; Doroshow, J. H. Characterization of the aqueous decomposition products of (+)1,2-bis(3,5-dioxopiperazinyl-1-yl)-propane (ICRF-187) by liquid chromatographic and mass spectral analysis. J. Pharm. Sci. 1991, 80, 338-340.
73. Hasinoff, B. B. An HPLC and spectrophotometric study of the hydrolysis of ICRF-187 (dexrazoxane, (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane) and its one-ring opened intermediates. Int J. Pharm. 1994, 107, 67-76.
74. Hasinoff, B. B. Pharmacodynamics of the hydrolysis-activation of the cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane. J. Pharm. Sci. 1994, 83, 64-67.
75. Dawson, K. M. Studies on the stability and cellular distribution of dioxopiperazines in cultured BHK-21S cells. Biochem. Pharmacol. 1975, 24, 2249-2253.
76. Livingston, D. C.; Creighton, A. M.; Fisher, S. W. In Advances in Antimicrobial and Antineoplastic Chemotherapy, Progress in Research and Clinical Applications, Proceedings of the VIIth International Congress of Chemotherapy Prague, 1971; Semonsky, M.; Hejzlar, M.; Masak, S., Eds.; University Park Press: Baltimore, 1972; Vol. II: Antineoplastic Chemotherapy and Radioprotectives, pp. 109-110.
77. Hellmann, K.; Field, E. O. Effect of ICRF 159 on the mammalian cell cycle: Significance for its use in cancer chemotherapy. J. Natl. Cancer Inst. 1970, 44, 539-543.
78. Sisco, J. M.; Stella, V. J. Is ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] unusually reactive for an imide? Pharm. Res. 1992, 9, 1076-1082.
79. Sisco, J. M.; Stella, V. J. An unexpected hydrolysis pH-rate profile, at pH values less than 7, of the labile imide, ICRF-187: (+)-1,2-bis(3,5-dioxopiperazin-1-yl)propane. Pharm. Res. 1992, 9, 1209-1214.
80. Beijnen, J. H.; van Gijn, R. Chemical stability of the cardioprotective agent ICRF-187 in infusion fluids. J. Parenter. Sci. Technol. 1993, 47, 166-171.
81. Herman, E. H.; Zhang, J.; Hasinoff, B. B.; Chadwick, D.; Clark, J. R. J.; Ferrans, V. J. Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron(III) displacement reactions of ICRF-187 and other bisdiketopiperazines. Cancer Chemother. Pharmacol. 1997, 40, 400-408.
82. Hasinoff, B. B. The interaction of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane), its hydrolysis product ICRF-198, and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin. Agents Actions 1989, 26, 378-385.
83. Hasinoff, B. B. The iron(III) and copper(II) complexes of adriamycin promote the hydrolysis of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane). Agents Actions 1990, 29, 374-381.
84. Buss, J. L.; Hasinoff, B. B. The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes. Agents Actons 1993, 40, 86-95.
85. Buss, J. L.; Hasinoff, B. B. Ferrous ion strongly promotes the ring opening of the hydrolysis intermediates of the antioxidant doxorubicin cardioprotective agent ICRF-187 (dexrazoxane). Arch. Biochem. Biophys. 1995, 317, 121-127.
86. Buss, J. L.; Hasinoff, B. B. Metal ion-promoted hydrolysis of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and its one-ring open hydrolysis products to its metal-chelating active form. J. Inorg. Biochem. 1997, 65, 251-256.
87. Houghton, R. P ; Williams, E. Synthesis of bis(imides) and bis(half amides) of N, N′-ethylenebis(iminodiacetic acid). J. Chem. Soc. Perkin Trans. / 1982, 2693-2696.
88. Nolan, K. B ; Murphy, T.; Hermanns, R. D.; Rahoo, H. Chelating agents as antitumour drugs: Formation of chelating agents from the antitumour pro-drug razoxane. Inorg. Chim. Acta 1990, 168, 283-288.
89. Daeid, N. N.; Nolan, K. B.; Ryan, L. P. Copper(II) complexes of hydrolysis products of the anticancer bis(3,5-dioxopiperazin-1-yl)alkanes. Displacement of co-ordinated carboxylate ligands by deprotonated amide groups in basic solution. J. Chem. Soc. Dalton Trans. 1991, 2301-2304.
90. Doroshow, J. H. In Anthracycline Antiobiotics, New Analogues, Methods of Delivery, and Mechanisms of Action; Priebe, W., Ed.; American Chemical Society: Washington, 1995; pp. 259-267.
91. Hasinoff, B. B ; Reinders, F. X.; Clark, V. The enzymatic hydrolysis-activation of the adriamycin cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane. Drug Metab. Dispos. 1991, 19, 74-80.
92. Hasinoff, B. B. Enzymatic ring-opening reactions of the chiral cardioprotective agent (+) (S)- ICRF-187 and its (-) (R)-enantiomer ICRF-186 by dihydropyrimidine amidohydrolase. Drug Metab. Dispos. 1993, 21, 883-888.
93. Hasinoff, B. B. Stereoselective hydrolysis of ICRF-187 (dexrazoxane) and ICRF-186 by dihydropyrimidine amidohydrolase. Chirality 1994, 6, 213-215.
94. Hasinoff, B. B.; Venkataram, S.; Singh, M.; Kuschak, T. I. Metabolism of the cardioprotective agents dexrazoxane (ICRF-187) and levrazoxane (ICRF-186) by the isolated hepatocyte. Xenobiotica 1994, 24, 977-987.
95. May, P. M.; Willes, M. J.; Williams, D. R.; Creighton, A. M. Metal binding by pharmaceuticals. Part 5. Interaction of Cd(II), Ni(II) and Pb(II) with the intracellular hydrolysis products of the anti-tumor agent ICRF 159 and its inactive homologue ICRF 192. Agents Actions 1984, 15, 449-453.
96. Huang, Z. X.; Creighton, A. M.; Williams, D. R. Metal binding properties of two homologues of razoxane, a bisdioxopiperazine antitumour drug. Inorg. Chim. Acta 1985, 107, L29-L32.
97. Sobol, M. M.; Amiet, R. G.; Green, M. D. In vitro evidence for direct complexation of ADR- 529/ICRF-187 [(+)-1,2-bis-(3,5-dioxo-piperazin-1-yl)propane] onto an existing ferric-anthracycline complex. Mol. Pharmacol. 1992, 41, 8-17.
98. Hasinoff, B. B.; Kala, S. V. The removal of metal ions from transferrin, ferritin and ceruloplasmin by the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane) and its hydrolysis product ADR-925. Agents Actions 1993, 39, 72-81.
99. Bull, C.; McClune, G. J.; Fee, J. A. The mechanism of Fe-EDTA catalyzed superoxide dismutation. J. Am. Chem. Soc. 1983, 105, 5290-5300.
100. Hasinoff, B. B. NADPH-cytochrome-P450 reductase promotes hydroxyl radical production by the iron complex of ADR-925, the hydrolysis product of ICRF-187 (dexrazoxane). Free Rad. Res. 1995, 22, 319-325.
101. Malisza, K. L.; Hasinoff, B. B. Doxorubicin reduces the iron(III) complexes of the hydrolysis products of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and produces hydroxyl radicals. Arch. Biochem. Biophys. 1995, 316, 680-588.
102. Malisza, K. L.; Hasinoff, B. B. Hydroxyl radical production by the iron complex of the hydrolysis product of the antioxidant cardioprotective agent ICRF-187 (dexrazoxane). Redox Rep. 1996, 2, 69-73.
103. Thomas, C.; Vile, G. F.; Winterbourn, C. C. The hydrolysis product of ICRF-187 promotes iron-catalysed hydroxyl radical production via the Fenton reaction. Biochem. Pharmacol. 1993, 45, 1967-1972.
104. Graf, E.; Mahoney, J. R.; Bryant, R. G.; Eaton, J. W. Iron-catalyzed hydroxyl radical formation. Stringent requirement for free iron coordination site. J. Biol. Chem. 1984, 259, 3620-3624.
105. Ryan, T. P.; Samokyszyn, V. M.; Dellis, S., Aust, S. D. Effects of (+)-1,2-bis(3,5-dioxopiperazin-1-yl)propane (ADR-529) on iron-catalyzed lipid peroxidation. Chem. Res. Toxicol. 1990, 3, 384-390.
106. 3+ reduction, lipid peroxidation, and CaATPase inactivation in heart microsomes exposed to adriamycin. Cancer Res. 1990, 50, 2307-2310.
107. Malisza, K. L.; Hasinoff, B. B. Inhibition of anthracycline semiquinone formation by ICRF-187 (dexrazoxane) in cells. Free Rad. Biol Med. 1996, 20, 905-914.
108. Zhang, Y.; Zhang, T.-M.; Zhao, B.-L.; Han, J.-K.; Chen, W.-C.; Xin, W.-J. Scavenging of probimane on semiquinone free radical formation by doxorubicin in rat heart. Acta Pharmacol. Sin. 1991, 12, 20-23.
109. Politi, P. M.; Rajagopalan, S.; Sinha, B. K. Free-radical formation by mitomycin C and its novel analogs in cardiac microsomes and the perfused rat heart. Biochim. Biophys. Acta 1989, 992, 341-348.
110. Shipp, N. G.; Dorr, R. T.; Alberts, D. S.; Dawson, B. V.; Hendrix, M. Characterization of experimental mitoxantrone cardiotoxicity and its partial inhibition by ICRF-187 in cultured neonatal rat heart cells. Cancer Res. 1993, 53, 550-556.
111. Shipp, N. G.; Dorr, R. T. Biochemical effects and toxicity of mitoxantrone in cultured heart cells. Adv. Exp. Med. Biol. 1991, 283, 821-825.
112. Sehested, M.; Jensen, P. B.; Sorensen, B. S.; Holm, B.; Friche, E.; Demant, E. J. F. Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem. Pharmacol. 1993, 46, 389-393.
113. Tewey, K. M.; Rowe, T. C.; Yang, L.; Halligan, B. D.; Liu, L. F. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984, 226, 466-468.
114. Bodley, A.; Liu, L. F.; Israel, M.; Seshadri, R.; Koseki, Y.; Giuliani, F. C.; Kirschenbaum, S.; Silber, R.; Potmesil, M. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA. Cancer Res. 1989, 49, 5969-5978.
115. Corbett, A. H.; Osheroff, N. When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chem. Res. Toxicol. 1993, 6, 585-597.
116. D'Arpa, P.; Liu, L. F. Topoisomerase-targeting antitumor drugs. Biochim. Biophys. Acta 1989, 989, 163-177.
117. Glisson, B. S.; Ross, W. E. DNA topoisomerase II- a primer on the enzyme and its unique role as a multidrug target in cancer chemotherapy. Pharmacol. Ther. 1987, 32, 89-106.
118. Anon. Dexrazoxane for cardiac protection against doxorubicin. Med. Lett. Drugs Ther. 1995, 37, 109-111.
119. Hasinoff, B. B.; Yalowich, J. C.; Ling, Y.; Buss, J. L. The effect of dexrazoxane (ICRF-187) on doxorubicin and daunorubicin-mediated growth inhibition of Chinese hamster ovary (CHO) cells. Anticancer Drugs 1996, 7, 558-567.
120. Supino, R. Influence of ICRF-159 or ICRF-186 on cytotoxicity of daunorubicin and doxorubicin. Tumori 1984, 70, 121-126.
121. Kano, Y.; Narita, T.; Suzuki, K.; Akutsu, M.; Suda, K.; Sakamoto, S ; Miura, Y. The effects of ICRF-154 in combination with other anticancer agents In vitro. Br. J. Cancer 1992, 66, 281-286.
122. Wadler, S.; Green, M. D ; Muggia, F. M. Synergistic activity of doxorubicin and bisdioxopiperazine (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) against the murine sarcoma S180 cell line. Cancer Res. 1986, 46, 1176-1181.
123. Wadler, S.; Green, M. D.; Basch, R.; Muggia, F. M Lethal and sublethal effects of the combination of doxorubicin and the bisdioxopiperazine, (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane ICRF-187, on murine sarcoma S180 In vitro. Biochem. Pharmacol. 1987, 36, 1495-1501.
124. Scambia, G.; Bitta, R. D.; Panici, P. B.; De Vincenzo, R.; Contu, G.; Ercoli, A.; Bonanno, G.; Pierelli, L.; Mancuso, S. Bisdioxopiperazine, (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane, (ICRF-187), enhances the antiproliferative effect of cisplatin on human ovarian cancer cells. Gynecol. Oncol. 1995, 57, 16-22.
125. Roca, J.; Ishida, R.; Berger, J. M.; Andoh, T.; Wang, J. C. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc. Natl. Acad. Sci. USA 1994, 91, 1781-1785.
126. Ishida, R.; Iwai, M.; Hara, A.; Andoh, T. The combination of different types of antitumor topoisomerase II inhibitors, ICRF-193 and VP-16, has synergistic and antagonistic effects on cell survival, depending on treatment schedule. Anticancer Res. 1996, 16, 2735-2740.
127. Hasinoff, B. B.; Kuschak, T. I.; Creighton, A. M.; Fattman, C. L.; Allan, W. P.; Thampatty, P.; Yalowich, J. C. Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II. Biochem. Pharmacol. 1997, 53, 1843-1853.
128. Weiss, G.; Kastner, S.; Brock, J.; Thaler, J.; Grunewald, K. Modulation of transferrin receptor expression by dexrazoxane (ICRF-187) via activation of iron regulatory protein. Mol. Pharmacol. 1997, 15, 1419-1424.
129. Tan, C.; Tasaka, H.; Yu, K. P.; Murphy, M. L.; Karnofsky, D. A. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Cancer 1967, 20, 333-353.
130. Lefrak, E. A.; Pitha, J.; Rosenheim, S.; Gottlieb, J. A. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973, 32, 302-314.
131. Herman, E. H.; Mhatre, R. M., Lee, I. P.; Waravdekar, V. S. Prevention of the cardiotoxic effects of adriamycin and daunomycin in the isolated dog heart. Proc. Soc. Exp. Biol. Med. 1972, 140, 234-239.
132. Herman, E. H.; Mhatre, R. M. Modification of some of the toxic effects of daunomycin (NSC- 82, 151) by pretreatment with the antineoplastic agent ICRF 159 (NSC-129, 943). Toxicol. Appl. Pharmacol. 1974, 27, 517-526.
133. Herman, E. H.; Ardalan, B.; Bier, C.; Waravdekar, V. S.; Krop, S. Reduction in daunorubicin lethality and myocardial alteration by pretreatment with ICRF-187 in Syrian Golden Hamster. Cancer. Treat Rep. 1979, 63, 89-92.
134. Fischer, V. W.; LaRose, L. S.; Wang, G. M. Mitigating effects of ICRF-159 (Razoxane) on a daunomycin-induced cardiomyopathy in mice. Drug Chem. Toxicol. 1982, 5, 155-164.
135. Fischer, V. W.; Wang, G. M.; Hobart, N. H. Mitigation of an anthracycline-induced cardiomyopathy by pretreatment with razoxane: a quantitative morphological assessment. Virchows Arch. B, Cell Pathol. Incl. Mol. Patriot. 1986, 51, 353-361.
136. Wang, G.; Finch, M.; Trevan, D.; Hellman, K. Reduction of daunomycin toxicity by razoxane. Br. J. Cancer 1981, 43, 871-877.
137. Herman, E. H.; El-Hage, A. N.; Ferrans, V. J.; Witiak, D. T. Reduction by ICRF-187 of acute daunorubicin toxicity in Syrian golden hamsters. Res. Commun. Chem. Pathol. Pharmacol. 1983, 40, 217-231.
138. Herman, E. H.; Ferrans, V. J.; Jordan, W.; Ardalan, B. Reducton of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits. Res. Commun. Chem. Pathol. Pharmacol. 1981, 31, 85-97.
139. Herman, E. H.; Ferrans, V. J. Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (±)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187). Cancer Res. 1981, 41, 3436-3440.
140. Herman, E. H.; Ferrans, V. J. Influence of vitamin E and ICRF-187 on chronic doxorubicin cardiotoxicity in miniature swine. Lab. Invest. 1983, 49, 69-77.
141. Herman, E. H.; El-Hage, A. N.; Creighton, A. M.; Witiak, D. T.; Ferrans, V. J. Comparison of the protective effect of ICRF-187 and structurally related analogues against acute daunorubicin toxicity in Syrian golden hamsters. Res. Commun. Chem. Pathol. Pharmacol. 1985, 48, 39-55.
142. Perkins, W. E.; Schroeder, R. L.; Carrano, R. A.; Imondi, A. R. Effect of ICRF-187 on doxorubicin-induced myocardial effects in the mouse and guinea pig. Br. J. Cancer 1982, 46, 662-667.
143. Alderton, P.; Gross, J.; Green, M. D. Rote of (±)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy. Cancer Res. 1990, 50, 5136-5142.
144. van Acker, S. A.; Kramer, K.; Voest, E. E.; Grimbergen, J. A.; Zhang, J.; van der Vijgh, W. J.; Bast, A. Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice. A new model to test potential protectors. Cancer Chemother. Pharmacol. 1996, 38, 95-101.
145. Hu, S. T.; Brandle, E.; Zhinden, G. Inhibition of cardiotoxic, nephrotoxic and neurotoxic effects of doxorubicin by ICRF-159. Pharmacology 1983, 26, 210-220.
146. Bernardini, N.; Danesi, R.; Macchiarini, P.; Del Tacca, M. ICRF-187 prevents ECG alterations induced by doxorubicin treatment in the rat. Proc. Am. Assoc. Cancer Res. 1990, 37, 443.
147. Herman, E. H.; el-Hage, A. N.; Ardalan, B. Comparison of the severity of the chronic cardiotoxicity produced by doxorubicin in normotensive and hypertensive rats. Toxicol. Appl Pharmacol. 1985, 78, 202-214.
148. Herman, E. H.; El-Hage, A.; Ferrans, V. J. Protective effect of ICRF-187 on doxorubicin- induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats. Toxicol. Appl. Pharmacol. 1988, 92, 42-53.
149. Zhang, J.; Herman, E. H.; Ferrans, V. J. Dendritic cells in the hearts of spontaneously hypertensive rats treated with doxorubicin with or without ICRF-187. Am. J. Pathol. 1993, 142, 1916-1926.
150. Herman, E. H.; Ferrans, V. J. Pretreatment with ICRF-187 provides long lasting protection against chronic daunorubicin cardiotoxicity in rabbits. Cancer Chemother. Pharmacol. 1986, 16, 102-106.
151. Villani, F.; Galimberti, M.; Monti, E.; Cova, D.; Lanza, E.; Rozza-Dionigi, A.; Favalli, L.; Poggi, P. Effect of ICRF-187 pretreatment against doxorubicin-induced delayed cardiotoxicity in the rat Toxicol. Appl. Pharmacol. 1990, 102, 292-299.
152. Yeung, T. K.; Jaenke, R. S.; Wilding, D.; Creighton, A. M.; Hopewell, J. W. The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat. Cancer Chemother. Pharmacol 1992, 30, 58-64.
153. Torre, P. D.; Popesta, A.; Pinciroli, G. Long-lasting effects of dexrazoxane against anthracacyline cardiotoxicity in rats. Toxicol. Pathol, 1996, 24, 398-402.
154. Herman, E. H.; Ferrans, V. J. Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity. Cancer Chemother. Pharmacol. 1993, 32, 445-449.
155. Agen, C.; Bernardini, N.; Danesi, R.; Torre, P. D.; Costa, M.; Tacca, M. D. Reducing doxorubicin toxocity in rat using deferred treatment with ADR-529. Cancer Chemother. Pharmacol. 1992, 30, 95-99.
156. Herman, E. H.; Ferrans, V. J.; Young, R. S.; Balazs, T. Examination of minoxidil-induced acute cardiotoxicity in miniature swine. Toxicol. 1988, 48, 41-51.
157. Dardir, M.; Herman, E. H.; Ferrans, V. J. Effects of ICRF-187 on the cardiac and renal toxicity of epirubicin in spontaneously hypertensive rats. Cancer Chemother. Pharmacol. 1989, 23, 269-275.
158. Verhoef, V.; Colborn, D.; Bell, V.; Filppi, J. Cardioprotective activity of ADR-529 for daunorubicin and idarubicin. Proc. Am. Assoc. Cancer Res. 1990, 31, 404.
159. Alderton, P. M.; Gross, J.; Green, M. D. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Res. 1992, 52, 194-201.
160. Al-Harbi, M. M.; Al-Gharably, N. M.; Al-Shabanah, O. A.; Al-Bekairi, A. M.; Osman, A. M. M.; Tawfik, H. N. Prevention of doxorubicin-induced nyocardial and haematological toxicities in rats by the iron chelator desferrioxamine. Cancer Chemother. Pharmacol. 1992, 31, 200-204.
161. Voest, E. E.; van Acker, A. B. E.; van Vijgh, W. J. F.; van Asbeck, B. S.; Bast, A. Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity. J. Mol. Cell Cardiol. 1994, 26, 1179-1185.
162. Herman, E. H.; Zhang, J.; Ferrans, V. J. Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats. Cancer Chemother. Pharmacol. 1994, 35, 93-100.
163. Yeung, T. K.; Jeffery, W. A.; Long, J.; Wilding, D.; Hopewell, J. W.; Creighton, A. M. ICRF-197: Ann. Oncol. 1992, 3 (Supp. 1), 114
164. Zhang, J.; Herman, E.H.; Ferrans, V. Effects of ICRF-186 [(L)1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] on the toxicity of doxorubicin in spontaneously hypertensive rats. Toxicol. 1994, 92, 179-192.
165. Herman, E. H.; Ferrans, V. J.; Sanchez, J. A. In Cancer Treatment and the
166. Wu, S. H.; Yang, Y. C.; Wang, Z. M. Role of oxygen radicals in adriamycin-induced nephrosis. Chin. Med. J. (Engl) 1990, 103, 283-289.
167. Gobe, G. C.; Axelsen, R. A.; Harmon, B. V.; Allan, D. J. Cell death by apoptosis following X-irradiation of the foetal and neonatal rat Kidney. Int. J. Rad. Biol. 1996, 54, 567-576.
168. Zhang, J.; Clark, J. R.; Herman, E. H.; Ferrans, V. J. Doxorubicin-induced apoptosis in spontaneously hypertensive rats: Differential effects in heart, kidney and intestine, and inhibition by ICRF-187. J. Mol. Cell Cardiol. 1996, 28, 1931-1943.
169. Verhoef, V.; Bell, V.; Filippi, J. Effect of the cardioprotective agent ADR-529 (ICRF-187) on the antitumor activity of doxorubicin. Proc. Am. Assoc. Cancer Res. 1988, 29, 273.
170. El-Hage, A.; Herman, E. H.; Ferrans, V. J. Reduction in the diabetogenic effect of alloxan in mice by treatment with the antineopiastic agent ICRF-187. Res. Commun. Chem. Pathol. Pharmacol. 1981, 33, 509-523
171. El-Hage, A. N.; Herman, E. H.; Ferrans, V. J. Examination of the protective effect of ICRF-187 and dimethyl sulfoxide against acetaminophen-induced hepatotoxicity in Syrian golden hamsters. Toxicol. 1983, 28, 295-303.
172. Fukuda, Y.; Herman, E. H.; Ferrans, V. J. Effect of ICRF-187 on the pulmonary damage induced by hyperoxia in the rat. Toxicol. 1992, 74, 185-202.
173. Holm, B.; Jensen, P. B.; Sehested, M. ICRF-187 rescue in etoposide treatment In vivo. A model targeting high dose topoisomerase II poisons to CNS tumors. Cancer Chemother. Pharmacol. 1996, 38, 203-209.
174. Hellmann, K.; Burrage, K. Control of malignant metastases by ICRF I59. Nature 1969, 224, 273-275.
175. Sausville, E. A.; Peisach, J.; Horwitz, S. B. Effect of chelating agents and metal ions on the degradation of DNA by bleomycin. Biochemistry 1978, 17, 2740-2746.
176. Tryka, A. F. ICRF 187 and polyhydroxyphenyl derivatives fail to protect bleomycin induced lung injury. Toxicol 1989, 59, 127-138.
177. Herman, E. H.; Hasinoff, B. B.; Zhang, J.; Raley, L. G.; Zhang, T.-M.; Fukada, Y.; Ferrans, V. J. Morphologic and morphometric evaluation of the effect of ICRF-187 on bleomycin-induced pulmonary toxicity. Toxicol. 1995, 98, 163-175.
178. Salsbury, A. J.; Burrage, K.; Hellmann, K. Histological analysis of the antimetastatic effect of (±)-1,2-bis(3,5-dioxopiperazin-1-yl)propane. Cancer Res. 1974, 34, 843-849.
179. Le Serve, A. W.; Hellmann, K. Metastases and the normalization of tumour blood vessels by ICRF 159: a new type of drug action. Br. Med J. 1972, 1, 597-601
180. Peters, L. J. A study of the influence of various diagnostic and therapeutic procedures applied to a murine squamous carcinoma on its metastatic behaviour. Br. J. Cancer 1975, 32, 355-365.
181. Pollard, M ; Burleson, G. R.; Lucker, T. P. The Prostrate 1976, 2, 1.
182. Atherton, A. The effect of (±) 1,2-bis(3,5-dioxopiperazin-1-yl) propane (ICRF 159) on liver metastases from a hamster lymphoma. Eur. J. Cancer 1975, 11, 383-388.
183. Pimm, M. V.; Baldwin, R. W. Influence of ICRF 159 and trition WR 1339 on metastases of a rat epithelioma. Br. J. Cancer 1975, 31, 62-67.
184. Hellmann, K.; Murkin, G. E. Synergism of ICRF 159 and radiotherapy in experimental tumours. Cancer 1974, 34, 1033-1039.
185. Kovacs, C. J.; Evans, M. J.; Schenken, L. L.; Burholt, D. R. ICRF-159 enhancement of radiation response in combined modality therapies. I. Time/dose relationships for tumour response. Br. J. Cancer 1979, 39, 516-523.
186. Kovacs, C. J.; Schenken, L. L.; Burholt, D. R. Therapeutic potentiation of combined cis-dichlorodiammineplatinum(II) and irradiation by ICRF-159. Int. J. Radiat. Oncol. Biol. Phys. 1979, 5, 1361-1364.
187. Taylor, I. W ; Bleehen, N. M. Changes in sensitivity to radiation and ICRF-159 during the life of monolayer cultures of EMT6 tumour line. Br. J. Cancer 1977, 35, 587-594.
188. Kimler, B. Interaction of razoxane and radiation on cultured Chinese hamster cells. J. Radiat. Oncol. Biol. Phys. 1982, 8, 1333-1338.
189. Newman, H. F.; Dunphy, E. P.; Bleehen, N. M.; Dische, S.; Saunders, M. I.; Des Rochers, C.; Workman, P.; Lenox-Smith, I.; Smithen, C. E. A comparative study of Ro 03-8799: racemic mixture and enantiomers. Br. J. Radiol. 1986, 59, 997-999.
190. Hellmann, K.; Rhomberg, W. Radiotherapeutic enhancement by razoxane. Cancer Treat. Rev. 1991, 18, 225-240.
191. Field, E. O.; Mauro, F.; Hellmann, K. Blood Cleaner of ICRF-159. Cancer Chemother. Rep. 1971, 55, 527-530.
192. Sadée, W.; Staroscik, J.; Finn, C.; Cohen, J. Determination of (±)-1,2-bis(3,5-dioxopiperazinyl)propane plasma levels in rats, rabbits, and humans by glc and mass fragmentography. J. Pharm. Sci. 1975, 64, 998-1001.
193. Mhatre, R. M.; Tew, K. D.; van Hennik, M. B.; Waravdekar, V. S.; Schein, P. S. Absorption, distribution and pharmacokinetics of ICRF-187 in dogs. Proc. Am. Assoc. Cancer Res. 1983, 24, 290.
194. McPherson, E.; Archila, R.; Schein, P. S.; Tew, K. D.; Mhatre, R. M. Preclinical Pharmacokinetics, disposition and metabolism of ICRF-187. Proc. Am. Assoc. Cancer Res 1984, 25, 1436.
195. Narang, P. K.; Baldwin, J. R.; Benjamin, E. J.; Bianchine, J. R. ADR-529: disposition of a cardioprotective agent in mice. Pharm. Res. 1988, 5, S189.
196. Baldwin, J. R.; Uhrig, B. A.; Imondi, A.; Narang, P. K. Disposition of cardioprotective agent ICRF-187 in rats. Pharm. Res 1988, 5, 5186.
197. Baldwin, J R.; Phillips, B. A.; Overmyer, S. K.; Hatfield, N. Z.; Narang, P. K. Influence of the cardioprotective agent dexrazoxane on doxorubicin pharmacokinetics in the dog. Cancer Chemother. Pharmacol. 1992, 30, 433-438.
198. Woodman, R. J.; Cysyk, R. L.; Kline, J.; Gang, M.; Venditti, J. M. Enhancement of the effectiveness of daunorubicin (NSC-82151) or Adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943). Cancer Chemother. Rep. 1975, Part 1, 59, 689-695.
199. Giuliani, F ; Cesazze, A. M.; Dimarco, A.; Savi, G. Studies in mice treated with ICRF-159 combined with daunorubicin and doxorubicin. Cancer. Treat. Rep. 1981, 65, 267-276.
200. Monti, E.; Sinha, B. K. Potentiation of doxorubicin cytotoxicity by (+)-1,2-bis-(3,5- dioxopiperazin-1-yl) propane (ICRF-187) in human leukemic HL-60 cells. Cancer Commun. 1990, 2, 145-149.
201. Gralla, E. J.; Coleman, G. R.; Jonas, A. M. Preclinical toxicology studies with ICRF-159. Cancer Chemother. Rep. 1974, 5, 1-7.
202. Levine, B. S.; Henry, M. C.; Port, C. D.; Rosen, E. Preclinical toxicologic evaluation of ICRF-187 in dogs. Cancer. Treat Rep. 1980, 64, 1211-1215.
203. Speyer, J. L.; Green, M. D.; Zeleniuch-Jacquotte, A.; Wernz, J. C.; Rey, M.; Sanger, J.; Kramer, E.; Ferrans, V.; Hochster, H.; Meyers, M.; Blum, R. H.; Feit, F.; Attubato, M.; Burrows, W.; Muggia, F. M. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J. Clin. Oncol. 1992, 10, 117-127.
204. Sandberg, J.; Goldin, A. Use of first generation transplants of a slow growing solid tumor for the evaluation of new cancer chemotherapeutic agents. Cancer Chemother. Rep. 1971, 55, 233-238.
205. Ahmann, D. L.; O'Connell, M. J.; Bisel, H. F.; Edmonson, J. H.; Hahn, R. G.; Frytak, S. Phase II study of dianhydrogalactitol and ICRF-159 in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy. Cancer. Treat Rep. 1977, 61, 81-82.
206. Gilbert, J. M.; Cassell, P.; Ellis, H.; Wastell, C.; Hermon-Taylor, J.; Hellmann, K. Adjuvant treatment with razoxane (ICRF 159) following resection of cancer of the stomach. Recent Results Cancer Res. 1979, 68, 217-221.
207. Eagan, B. T.; Carr, D. T.; Coles, D. T.; Rubin, J.; Frytak, S. ICRF 159 versus polychemotherapy in non-small cell lung cancer. Cancer. Treat. Rep. 1979, 60, 947-948.
208. Gilbert, J. M.; Hellmann, K.; Evans, M.; Cassell, P. G.; Taylor, R. H.; Stoodley, B.; Ellis, H.; Wastell, C. Randomized trial of oral adjuvant razoxane (ICRF 159) in resectable colorectal cancer five-year follow-up. Brit J. Surg. 1986, 73, 446-450.
209. Hellmann, K.; Gilbert, J.; Evans, M., Cassell, P.; Taylor, R. Effect of razoxane on metastases from colorectal cancer. Clin. Exp. Metastasis 1987, 5, 3-8.
210. Langleben, A.; Ahlgren, P.; Burdette-Radoux, S.; et al. Ultra high dose anthracycline combination therapy with peripheral blood stem cell (PBSC), G-CSF and ADR-529 support. Proc. Am. Soe. Clin. Oncol. 1995, 14, Abst 948.
211. Steinherz, L. J.; Steinherz, P. G.; Tan, C. T. C.; Heller, G.; Murphy, M. L. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991, 266, 1672-1677.
212. Bu'Lock, F. A.; Gabriel, H. M.; Oakhill, A.; Mott, M. G.; Martin, R. P. Cardioprotection by ICRF 187 against high dose anthracycline toxicity in children with malignant disese. Br. Heart J. 1993, 70, 185-188.
213. Schiavetti, A.; Castello, M. A.; Versacci, P.; Varrasso, G.; Padula, A.; Ventriglia, F.; Wemer, B.; Colloridi, V. Use of ICRF-187 for prevention of anthracycline cardiotoxicity in children: preliminary results. Pediatr. Hematol. Oncol. 1997, 14, 213-222.
214. Hellmann, K.; Hutchinson, G.; Henry, K. Mitozantrone therapeutic index improvement by gangliosides. Cancer Treat. Rev. 1987, 14, 373-378.
215. Hochster, H.; Wasserheit, C.; Speyer, J. Cardiotoxicty and cardioprotection during chemotherapy. Curr. Opin. Oncol. 1995, 7, 304-309.
216. Horton, J. J.; Wells, R. S. Razoxane: a review of 6 years' therapy in psoriasis. Br. J. Dermatol. 1983, 109, 669-673.
217. Atherton, D. J.; Wells, R. S.; Hellmann, K. Razoxane (ICRF 159) in psoriasis [letter]. Lancet 1976, 2, 1296.
218. Le Serve, A. W.; Hellmann, K. Metastases and the normalization of tumour blood vessels by ICRF 159: A new type of drug action. Br. Med. J. 1972, 1, 597-601.
219. Kingston, R. D.; Hellmann, K. Razoxane for Crohn's colitis and non-specific proctitis. Br. J. Clin. Pract. 1992, 46, 252-255.
220. Gibbs, K.; Walshe, J. M. The effect of certain chelating compounds on the urinary excretion of copper by the rat: observations on their clinical significance. Clin. Sci. Mol. Med. 1977, 53, 317-320.
221. Hellmann, K.; Goold, M; Higgins, N., Phillips, R. H. Responses of liver metastases to radiotherapy and razoxane. J. R. Soc. Med. 1992, 85, 136-138.
222. Sharpe, H. B. A.; Field, E. O.; Hellmann, K. Mode of action of the cytostatic agent 'ICRF 159'. Nature 1970, 226, 524-526.
223. Cheng, K. L.; Ueno, K.; Imamura, T., Eds. CRC Handbook of Organic Analytical Reagents; CRC Press: Boca Raton, 1982; pp. 215-216